Apollon Wealth Management
ABCL icon

Apollon Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Apollon Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-40,000
Closed -$314K – 1646
2026
Q2 		$314K Buy
+40,000
New +$196K ﹤0.01% 1241

Other funds holding ABCL

TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Guardian Partners
Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return
Citizens Financial Group
Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
DKM Wealth Management
DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return
Lantern Wealth Advisors
Lantern Wealth Advisors Melville, New York $232M AUM 16.88% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Apollon Wealth Management's ABCL Position: Q3 2026 in Review

Apollon Wealth Management sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 40,000 shares — an estimated $314K sold.

Apollon Wealth Management first reported a position in ABCL in Q2 2026 and held it in 1 quarter. The position peaked at $314K in Q2 2026. 15 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Apollon Wealth Management reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
  • Apollon Wealth Management sold 40,000 AbCellera Biologics shares in Q3 2026, an estimated $314K.
  • Apollon Wealth Management first reported a position in AbCellera Biologics in Q2 2026 and held it in 1 quarter.
  • Apollon Wealth Management's AbCellera Biologics position peaked at $314K in Q2 2026.
  • 15 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Apollon Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.